Suppr超能文献

抗A群链球菌糖缀合物疫苗的研究进展。

Progress towards a glycoconjugate vaccine against Group A Streptococcus.

作者信息

Burns Keira, Dorfmueller Helge C, Wren Brendan W, Mawas Fatme, Shaw Helen A

机构信息

Vaccine Division, Scientific Research & Innovation Group, MHRA, Potters Bar, UK.

Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, UK.

出版信息

NPJ Vaccines. 2023 Mar 28;8(1):48. doi: 10.1038/s41541-023-00639-5.

Abstract

The Group A Carbohydrate (GAC) is a defining feature of Group A Streptococcus (Strep A) or Streptococcus pyogenes. It is a conserved and simple polysaccharide, comprising a rhamnose backbone and GlcNAc side chains, further decorated with glycerol phosphate on approximately 40% GlcNAc residues. Its conservation, surface exposure and antigenicity have made it an interesting focus on Strep A vaccine design. Glycoconjugates containing this conserved carbohydrate should be a key approach towards the successful mission to build a universal Strep A vaccine candidate. In this review, a brief introduction to GAC, the main carbohydrate component of Strep A bacteria, and a variety of published carrier proteins and conjugation technologies are discussed. Components and technologies should be chosen carefully for building affordable Strep A vaccine candidates, particularly for low- and middle-income countries (LMICs). Towards this, novel technologies are discussed, such as the prospective use of bioconjugation with PglB for rhamnose polymer conjugation and generalised modules for membrane antigens (GMMA), particularly as low-cost solutions to vaccine production. Rational design of "double-hit" conjugates encompassing species specific glycan and protein components would be beneficial and production of a conserved vaccine to target Strep A colonisation without invoking an autoimmune response would be ideal.

摘要

A群碳水化合物(GAC)是A群链球菌(化脓性链球菌)的一个决定性特征。它是一种保守且简单的多糖,由鼠李糖主链和N-乙酰葡糖胺侧链组成,约40%的N-乙酰葡糖胺残基上还带有甘油磷酸修饰。其保守性、表面暴露性和抗原性使其成为A群链球菌疫苗设计的一个有趣焦点。含有这种保守碳水化合物的糖缀合物应该是构建通用A群链球菌候选疫苗这一成功任务的关键方法。在这篇综述中,将讨论A群链球菌主要碳水化合物成分GAC的简要介绍,以及各种已发表的载体蛋白和偶联技术。为了构建经济实惠的A群链球菌候选疫苗,特别是针对低收入和中等收入国家(LMICs),应该仔细选择成分和技术。为此,将讨论一些新技术,例如与PglB进行生物偶联用于鼠李糖聚合物偶联的前瞻性应用以及膜抗原通用模块(GMMA),特别是作为疫苗生产的低成本解决方案。合理设计包含物种特异性聚糖和蛋白质成分的“双靶点”缀合物将是有益的,生产一种针对A群链球菌定植且不会引发自身免疫反应的保守疫苗将是理想的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验